
Craig Thelwell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9480353/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry. Analytical Biochemistry, 2022, 638, 114413.	2.4	1
2	A new WHO reference reagent for activated blood coagulation factor X (FXa), human (15/102). Journal of Thrombosis and Haemostasis, 2020, 18, 255-257.	3.8	1
3	Investigating the functional relationship between streptokinase variants from Group A Streptococcus, and associated M-like proteins. Access Microbiology, 2020, 2, .	0.5	0
4	Investigating the impact of M1 protein from Group A Streptococcus on fibrin clot formation, structure and fibrinolytic potential. Access Microbiology, 2020, 2, .	0.5	0
5	Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 695-697.	3.8	0
6	Structure, Mechanical, and Lytic Stability of Fibrin and Plasma Coagulum Generated by Staphylocoagulase From Staphylococcus aureus. Frontiers in Immunology, 2019, 10, 2967.	4.8	5
7	An international collaborative study to calibrate the WHO 2nd International Standard for Ancrod (15/106) and the WHO Reference Reagent for Batroxobin (15/140): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1003-1006.	3.8	4
8	Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thrombosis Research, 2018, 163, 105-116.	1.7	41
9	Mechanism of plasmin generation by S100A10. Thrombosis and Haemostasis, 2017, 117, 1058-1071.	3.4	21
10	Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes. PLoS ONE, 2017, 12, e0170936.	2.5	13
11	An International Collaborative Study to establish the World Health Organization 4th International Standard for Plasmin (13/206): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 215-218.	3.8	1
12	Biological Standards for Potency Assignment to Fibrinolytic Agents Used in Thrombolytic Therapy. Seminars in Thrombosis and Hemostasis, 2014, 40, 205-213.	2.7	7
13	An International Collaborative Study to establish the WHO 2nd International Standard for High Molecular Weight Urokinase: communication from SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 415-417.	3.8	2
14	An international collaborative study to establish the World Health Organization 2nd International Standard for FactorÂVII Concentrate: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1750-1753.	3.8	0
15	Fractal Kinetic Behavior of Plasmin on the Surface of Fibrin Meshwork. Biochemistry, 2014, 53, 6348-6356.	2.5	11
16	Biosimilars: the process is the product. The example of recombinant streptokinase. Journal of Thrombosis and Haemostasis, 2014, 12, 1229-1233.	3.8	9
17	Differential scanning fluorimetry: Rapid screening of formulations that promote the stability of reference preparations. Journal of Pharmaceutical and Biomedical Analysis, 2013, 77, 163-166.	2.8	33
18	Regulation of fibrinolysis by Câ€ŧerminal lysines operates through plasminogen and plasmin but not tissueâ€ŧype plasminogen activator. Journal of Thrombosis and Haemostasis, 2012, 10, 2354-2360.	3.8	70

CRAIG THELWELL

#	Article	IF	CITATIONS
19	The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood, 2011, 117, 661-668.	1.4	118
20	An international collaborative study to establish the WHO 1st international standard for alphaâ€1â€antitrypsin. Vox Sanguinis, 2011, 101, 83-89.	1.5	5
21	An international collaborative study to establish the WHO 1st international standards for C1â€inhibitor, plasma and concentrate. Journal of Thrombosis and Haemostasis, 2011, 9, 2097-2099.	3.8	9
22	Fibrinolysis standards: A review of the current status. Biologicals, 2010, 38, 437-448.	1.4	6
23	Fibrin Binding and the Regulation of Plasminogen Activators during Thrombolytic Therapy. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 212-223.	1.0	30
24	An international collaborative study to investigate a proposed reference method for the determination of potency measurements of fibrinolytics in absolute units. Journal of Thrombosis and Haemostasis, 2007, 5, 412-414.	3.8	7
25	The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. Journal of Thrombosis and Haemostasis, 2007, 5, 804-811.	3.8	51
26	The poor quality of streptokinase products in use in developing countries. Journal of Thrombosis and Haemostasis, 2005, 3, 1092-1093.	3.8	14
27	Regulatory frameworks in developing countries. Nature Biotechnology, 2005, 23, 413-413.	17.5	3
28	Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Letters, 2005, 579, 3303-3309.	2.8	30
29	Inhibition of Catalytic and Glucan-Binding Activities of a Streptococcal GTF Forming Insoluble Glucans. Caries Research, 2002, 36, 353-359.	2.0	15
30	An SmtB-like repressor from Synechocystis PCC 6803 regulates a zinc exporter. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10728-10733.	7.1	171